Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse
neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract …

These guidelines update previous guidance published in 2005. They have been revised by
a group who are members of the UK and Ireland Neuroendocrine Tumour Society with …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Importance The incidence and prevalence of neuroendocrine tumors (NETs) are thought to
be rising, but updated epidemiologic data are lacking. Objective To explore the evolving …

PURPOSE Patients with advanced pancreatic neuroendocrine tumors (NETs) have few
treatment options that yield objective responses. Retrospective and small prospective …

M. Pavel a D. O'Toole b F. Costa c J. Capdevila d D. Gross e R. Kianmanesh f E. Krenning g
U. Knigge h R. Salazar i U.-F. Pape a K. Öberg j all other Vienna Consensus Conference …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

Purpose Somatostatin analogs are indicated for symptom control in patients with
gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs …

Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …

BACKGROUND. Temozolomide is an active agent in metastatic pancreatic endocrine
carcinomas. In vitro data indicate that the combination of capecitabine and temozolomide is …